GlaxoSmithKline PLC (GSK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

GlaxoSmithKline PLC (GSK)

50.70

+0.03 (0.06%)

as of Jun 18, 2026, 11:33:53 pm Market Open.

58 watching

COMMENT

UK-based international big pharmaceutical. Has drugs coming off of patent. 5.5% dividend should be safe.

DON'T BUY

He is not a player in the pharmaceutical industry. As soon as somebody comes up with a big drug, it instantly gets cloned by generics. Even FDA approved drugs are having adverse effects.

COMMENT

Have had some difficulties so there has been a sell off. Great depth in their management team. Reasonable pipeline.

BUY

Their patent expires this year. Are being evaluated, will probably sell. Recommends Johnson & Johnson instead. JNJ-N

SELL

A volatile uptrend. The five year chart shows a "double top" has broken below the valley between the double top, which is a signal to sell.

TOP PICK

Growth in revenue, earnings, cash flow and earnings per share shall not better than its peers. Stable of products is very, very good. Good dividend.

BUY

Likes the pharmaceutical sector. The whole pharmaceutical area is cheap. Has a good pipeline. Pays a good dividend. Cheap. Well run.

DON'T BUY

A lot of trouble with these companies is having access to new products. They are so large now they have to continually feed the pipeline at an accelerated rate by acquiring at higher prices.

PAST TOP PICK

(A Top Pick May 8/06. Down 4%.) Pays at 3.5% dividend.

TOP PICK

Have increased the products in their pipeline. AA credit. 3.5% yield. Good long-term outlook.

BUY

5% dividend. The European pharmaceuticals have been in better shape generally than their US counterparts, so they are probably a better value story than this one. They’re looking to acquire to help their drug pipeline.

BUY

The 2nd largest pharmaceutical supplier globally. They also have good health care as well. Have an excellent pipeline, good dividend and good management.

BUY

Buying it now for 2005/2006 because, looking down the road, they are getting a 3.5/4% yield. A great way to play India.

TOP PICK

Dividend yield of more than 5%. They have a major portion of the pharmaceutical industry in India. May have to be patient.

WEAK BUY

They don't have a great pipeline. Have good profit margins on some vaccines and AIDS medications. The price is decent.

Showing 76 to 90 of 99 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

GlaxoSmithKline PLC (GSK)